Inhibitory actions of *Pseuderanthemum palatiferum* (Nees) Radlk. leaf ethanolic extract and its phytochemicals against carbohydrate-digesting enzymes

Pawitra Pulbutr, Somsak Nualkaew, Sakulrat Rattanakiat, Benjamart Cushnie, Achida Jaruchotikamol

**ARTICLE INFO**

**Article history:**
Received 15 Sep 2015
Received in revised form 28 Sep 2015
Accepted 23 Oct 2015
Available online 19 Dec 2015

**Keywords:**
*Pseuderanthemum palatiferum*
Diabetes mellitus
α-Amylase
α-Glucosidase
Postprandial blood glucose

**ABSTRACT**

**Objective:** To investigate the effects of the leaf ethanolic extract of *Pseuderanthemum palatiferum* (PPE) and its isolated phytochemicals, stigmasterol and sitosterol-3-O-glucopyranoside, against α-amylase and α-glucosidase enzyme activities both *in vitro* and *in vivo*.

**Methods:** A concentration of maltose, which is a product released in α-amylase-catalyzing reaction, was used as an index of *in vitro* α-amylase activity. Meanwhile, *in vitro* α-glucosidase enzyme activity was indicated by the amount of liberated *p*-nitrophenol in α-glucosidase-catalyzing reaction. *In vivo* α-amylase and α-glucosidase enzyme activities were evaluated in the normal rats by using oral starch tolerance test and oral sucrose tolerance test, respectively.

**Results:** PPE exerted a concentration-dependent inhibitory action against both α-amylase and α-glucosidase *in vitro* with the IC₅₀ values of (11.79 ± 8.10) mg/mL and (1.00 ± 0.11) mg/mL, respectively. Stigmasterol and sitosterol-3-O-glucopyranoside also exerted an *in vitro* α-amylase inhibition with the IC₅₀ values of (59.41 ± 8.22) μg/mL and (111.19 ± 9.02) μg/mL, respectively. However, these phytochemicals did not produce a concentration-dependent inhibition against *in vitro* α-glucosidase activity. PPE and its isolated phytochemicals significantly decreased the blood glucose levels at *t* = 30 min in the oral starch tolerance test. From the sucrose tolerance test, only PPE but not its isolated phytochemicals significantly caused a depletion in the blood glucose levels at *t* = 30 min.

**Conclusions:** These results indicate an inhibitory action against carbohydrate-digesting enzymes as the anti-diabetic mechanism of action of PPE. Nonetheless, further clinical study is required to justify its role in the treatment of diabetes.

1. Introduction

Diabetes mellitus (DM) is a chronic metabolic disorder, characterized by an elevation of plasma glucose levels as a result of dysfunctions in insulin secretion and/or insulin actions. A prevalence of DM, especially type 2 DM, has continuously raised with the estimated global prevalence of 9% among adults in 2014 [1]. Chronic hyperglycemia evolved from diabetes ultimately leads to a pathogenesis of chronic diabetic complications especially cardiovascular disease, which is a major leading cause of death in diabetic patients [1]. In addition to fasting plasma glucose, postprandial (after-meal) plasma glucose plays a crucial role in the control of diabetes and its complications. Postprandial hyperglycemia contributes to a destruction of pancreatic β-cells and the developments of both micro- and macro-vascular complications [2,3]. A level of postprandial plasma glucose is mainly regulated by the function of carbohydrate-digesting enzymes in the intestine specifically α-amylase and α-glucosidase. Pancreatic α-amylase enzyme catalyzes a breakdown of 1–4 glycosidic bond of starch, whilst intestinal α-glucosidase is essential for a digestion of oligosaccharides and disaccharides [4]. These two enzymes...
thus serve as a target for a regulation of postprandial plasma glucose levels. 

_Pseudantherum palatiferum_ (Nees) Radlk. (_P. palatiferum_) has been used as a folk medicine for the treatment of diabetes in several Southeast Asian countries. The fasting plasma glucose-lowering effect of the plant’s leaf ethanolic extract and its isolated phytochemicals were evidenced in the streptozotocin-induced diabetic rats [5,6]. Our previous study showed that the leaf ethanolic extract of _P. palatiferum_ (PPE) possessed antilipolytic, antioxidant and _in vitro_ α-amylase inhibitory activities [7]. However, it is not known whether the extract exerts its inhibitory action against carbohydrate-digesting enzymes _in vivo_. Additionally, the plant extract-derived phytochemical which acts as an enzyme inhibitor has not been documented yet. The current study thus aimed to investigate the effects of PPE and its major isolated phytochemicals against α-amylase and _α_-d-glucosidase enzyme activities both _in vitro_ and _in vivo_.

2. Materials and methods

2.1. Preparation of PPE extract

The leaves of _P. palatiferum_ were collected from the plantation in Roi Et Province, Thailand. The authentication of the specimens was performed by the Plant Varieties Protection Division, Department of Agriculture, Ministry of Agriculture and Cooperatives. A voucher is collected at the Herbarium of Pharmaceutical Chemistry and Natural Product Research Unit, the Faculty of Pharmacy, Mahasarakham University, Thailand (code: MSU.PH-ACA-P1). The leaves were dried at 50 °C for 45 h in a hot-air oven and subsequently macerated with 80% ethanol in 1:10 ratio for 7 days. The extract was evaporated by using a rotary evaporator (Heidolph Laborota 4000, Germany) followed by a freeze dryer (Christ Alpha 1–4, Germany). PPE with the yield (%) of 12.7% w/w was then achieved. The extract was kept freezing at ~20 °C until use.

2.2. Isolation of the phytochemicals from PPE

Thin layer chromatography was conducted using normal-phase silica gel 60 F_{254} (Merck, Germany) on precoated aluminium plates. UV light (254 nm) and anisaldehyde-sulphuric acid spray reagent were used for detection. Column chromatography was carried out using silica gel 60 (0.063–0.200 mm; Merck, Germany). The melting point was obtained by using a Buchi melting point meter (Switzerland). UV spectra were obtained from a JASCO V530 UV/Vis spectrophotometer (Japan), while IR spectra were recorded with a Perkin Elmer Fourier transform infrared spectroscopy spectrometer (Germany). The mass spectra were obtained using a Bruker MicroTOF ESI-TOF (USA) spectrometry double-focusing probe at 70 eV, while nuclear magnetic resonance (NMR) spectra (1D and 2D) were measured on a Varian Mercury Plus 400 (USA) at 400 MHz for _1^H_ NMR and 100 MHz for _13^C_ NMR spectra. Solvents were of analytical grade such as _n_-hexane (Lab-Scan, Ireland), dichloromethane (CH₂Cl₂), ethyl acetate (EtOAc), methanol (MeOH) (Carlo Erba, Italy), and ethanol (EtOH) (Merck, Germany).

The procedure was similar to that described previously [6]. Concisely, the PPE was suspended in 80% MeOH and partitioned successively with _n_-hexane extract. The _n_-hexane extract was chromatographed on a silica gel column and eluted with gradient of _n_-hexane and EtOAc (100:0, 80:20, 70:30, 50:50, 30:70, 20:80 and 0:100 v/v), each portion of 500 mL. These elutes were collected in a series of test tubes with 20 mL in each fraction. The homogeneity of the eluted was monitored by thin layer chromatography and the identical fractions were combined to afford five fractions. Fraction 1 was rechromatographed on a silica gel column and eluted with _n_-hexane: EtOAc (8:2 v/v) to afford stigmasterol. Fraction 5 was precipitated with EtOAc to yield sitosterol-3-O-β-D-glucopyranoside.

2.3. In vitro study

2.3.1. _α_-Amylase enzyme activity assay

The _α_-amylase enzyme activity assay was performed according to the method of Ali _et al._ with slight modifications [8]. Briefly, a mixture of 200 µL of freshly prepared porcine pancreatic _α_-amylase (4 unit/mL) and 40 µL of the sample was prepared and incubated at 25 °C for 5 min. Potato starch solution (0.5% w/v, 400 µL) and distilled water (160 µL) were subsequently added into the mixture and incubated at 25 °C for further 3 min. A 200 µL volume of the mixture was added into a new microfuge tube containing 100 µL of 3,5-dinitrosalicylic acid color reagent solution (96 mmol/L 3,5-dinitrosalicylic acid and 5.31 mol/L sodium potassium tartarate in 2 mol/L NaOH) and then heated at 85 °C for 15 min. The optical density of the mixture was measured at the wavelength of 540 nm. The absorbance of the colored sample was subtracted by the absorbance of the blank in order to obtain the exact absorbance of the mixture. The amount of generated maltose, calculated from the maltose standard curve, was used as an index of _α_-amylase enzyme activity. Percent reaction was obtained with the following equation: 

% Reaction = \( \frac{\text{OD of negative control} - \text{OD of sample}}{\text{OD of negative control}} \times 100 \).

Percent inhibition was calculated as 100 - % reaction. The concentration-inhibitory response curve was plotted by using GraphPad Prism software version 6.0.

2.3.2. _α_-Glucosidase enzyme activity assay

The _α_-glucosidase enzyme activity was examined following the protocol of Elya _et al._ with slight modifications [9]. The reaction mixture containing 10 µL of sample, 250 µL of _p_-nitrophenyl_α_-glucopyranoside (_p_-NPG; 5 mmol/L) and 490 µL of phosphate buffer (100 mmol/L, pH 6.8) was prepared and incubated at 37 °C for 5 min. A 250 µL volume of _α_-glucosidase enzyme (0.15 unit/mL) was added into the mixture and then incubated for further 15 min at 37 °C. A 250 µL volume of the mixture was then transferred into a new microfuge tube containing 500 µL of Na₂CO₃. The optical density (OD) of the mixture was measured at the wavelength of 405 nm. The amount of _p_-nitrophenol released from _α_-glucosidase-catalyzing reaction was used as an index of _α_-glucosidase enzyme activity. The percentage of inhibition was calculated as the following equation: 

% Inhibition = \( \frac{\text{OD of negative control} - \text{OD of sample}}{\text{OD of negative control}} \times 100 \).

The concentration-inhibitory response curve was plotted by using GraphPad Prism software version 6.0.

2.4. In vivo study

2.4.1. Experimental animals

Male Wistar rats weighing 150–170 g were obtained from the National Laboratory Animal Center, Mahidol University, Thailand and housed at a constant temperature of (25 ± 1) °C.
with a 12 h dark–light cycle. The rats were fed ad libitum with free access to water. The oral carbohydrate tolerance test was performed after 1-week acclimatization. All procedures with the animals were approved by the Animal Research Ethics Committee, Mahasarakham University, Thailand (No. 009/2556).

2.4.2. Oral starch tolerance test

The rats were divided into nine groups (n = 5 per group) and fasted overnight but had free access to water. Groups 1–3 were treated orally with PPE at the doses of 250, 500 and 1 000 mg/kg body weight. Stigmasterol and sitosterol-3-O-β-D-glucopyranoside, isolated from PPE, were given to Groups 4–7 at the doses of 5 and 10 mg/kg, respectively. Group 8 was treated with acarbose (a positive control) at the dose of 10 mg/kg body weight, whilst Group 9 was orally fed with 2% Tween 80 (a vehicle control). After treatment with the designated agents for 10 min, all rats were orally given with starch (3 g/kg body weight). The blood glucose levels were measured by using a glucometer (Accu-Chek® Active, Roche Diagnostic, Thailand) at before (t = 0) and at 30, 60 and 120 min after starch feeding.

2.4.3. Oral sucrose tolerance test

The rats were divided into nine groups (n = 5 per group) and treated with the similar treatments as those in the oral starch tolerance test. All rats were fed with sucrose (4 g/kg body weight) solution at 10 min after the treatment. The blood glucose levels were measured at before (t = 0) and at 30, 60 and 120 min after sucrose feeding.

2.5. Statistical analysis

All data from the in vitro experiments were expressed as mean ± SD, except the IC50 values were expressed as mean ± SEM. The in vivo data were presented as mean ± SEM. The data were statistically analyzed using One-way analysis of variance (ANOVA) followed by the Bonferroni post-hoc test. Statistically significant differences were indicated by a P-value of <0.05.

3. Results

3.1. Isolation of stigmasterol and sitosterol-3-O-β-D-glucopyranoside from PPE

Stigmasterol was obtained as white needle crystals, melting point 135–136 °C and its molecular formula was assigned to be C29H48O according to its mass spectrum (m/z 599 [M+Na]+). The stigmasterol and sitosterol-3-O-β-D-glucopyranoside were identified by comparing their physical and spectroscopic data of IR, NMR and mass spectra with the reported in the literature [6] and analyzing their 2D NMR spectral data.

3.2. Inhibitory effects of PPE against in vitro α-amylase enzyme activity

PPE at the concentrations of 10, 20 and 30 mg/mL significantly inhibited α-amylase enzyme activity (Table 1). The maximal inhibitory of (89.79 ± 3.42)% was found at the PPE concentration of 10 mg/mL (mean ± SEM, n = 6) and analyzing their 2D NMR spectral data.

<table>
<thead>
<tr>
<th>PPE concentrations (mg/mL)</th>
<th>Inhibition</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0.00 ± 1.98</td>
</tr>
<tr>
<td>0.1</td>
<td>−16.37 ± 7.87</td>
</tr>
<tr>
<td>0.3</td>
<td>−22.64 ± 7.87</td>
</tr>
<tr>
<td>1</td>
<td>−69.09 ± 11.65</td>
</tr>
<tr>
<td>3</td>
<td>11.87 ± 12.86</td>
</tr>
<tr>
<td>10</td>
<td>49.34 ± 6.82*</td>
</tr>
<tr>
<td>20</td>
<td>88.87 ± 3.78*</td>
</tr>
<tr>
<td>30</td>
<td>8.979 ± 3.42*</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SD, n = 6. *: P < 0.05 when compared with vehicle control (dimethyl sulfoxide). One-way ANOVA and Bonferroni post-hoc test were used.

3.3. Inhibitory effects of PPE against in vitro α-glucosidase enzyme activity

The experiment on α-amylase enzyme kinetics was then subsequently studied by varying substrate concentrations at 0.5%, 1%, 1.5% and 2% w/v with the fixed PPE concentration of 10 mg/mL (approximate IC50). Lineweaver–Burk plot was drawn to determine the enzyme kinetics in the presence and the absence of PPE (Figure 1A). PPE (10 mg/mL) caused a decrease

Figure 1. Kinetics analysis of α-amylase inhibition by (A) PPE and acarbose, (B) PPE-derived stigmasterol and (C) PPE-derived sitosterol-3-O-β-D-glucopyranoside.

Data are expressed as mean ± SEM, n = 6. Lineweaver–Burk plot of the reaction against α-amylase in the presence or absence of the test agents.
in maximal rate of reaction ($V_{\text{max}}$) and an increase in Michaelis constant ($K_m$) (Table 3). This mode of changes in enzyme kinetics was similar to that caused by acarbose.

### 3.3. Inhibitory effects of PPE-derived stigmasterol against in vitro $\alpha$-amylase enzyme activity

Stigmasterol, isolated from PPE, at the concentrations of 300 and 1000 $\mu$g/mL significantly inhibited $\alpha$-amylase enzyme activity with the maximal inhibition of (42.68 ± 3.69)$\%$ ($n = 3$) achieved at the concentration of 1000 $\mu$g/mL (Table 4). IC$_{50}$ of PPE-derived stigmasterol-3-O-$\beta$-D-glucopyranoside against $\alpha$-amylase enzyme activity, %. 

<table>
<thead>
<tr>
<th>Stigmasterol concentrations ($\mu$g/mL)</th>
<th>Inhibition</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0.00 ± 1.51</td>
</tr>
<tr>
<td>1</td>
<td>0.86 ± 11.77</td>
</tr>
<tr>
<td>3</td>
<td>0.71 ± 6.03</td>
</tr>
<tr>
<td>10</td>
<td>1.12 ± 4.34</td>
</tr>
<tr>
<td>30</td>
<td>15.22 ± 5.66</td>
</tr>
<tr>
<td>100</td>
<td>21.13 ± 4.61</td>
</tr>
<tr>
<td>300</td>
<td>39.80 ± 4.58$^a$</td>
</tr>
<tr>
<td>1000</td>
<td>42.68 ± 3.69$^a$</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SD, $n = 3$. $^a$: $P < 0.05$ when compared with vehicle control (dimethyl sulfoxide: Tween 80: Span 20 = 2:1:1); One-way ANOVA and Bonferroni post-hoc test were used.

(59.41 ± 8.22) $\mu$g/mL (mean ± SEM, $n = 3$) was obtained from a concentration-inhibitory response curve of PPE-derived stigmasterol (Table 2). Lineweaver–Burk plot was drawn from the $\alpha$-amylase enzyme kinetics study in the absence and the presence of 60 $\mu$g/mL stigmasterol (approximate IC$_{50}$) (Figure 1B). Stigmasterol produced changes in both $V_{\text{max}}$ and $K_m$ with a decrease in $V_{\text{max}}$ and an increase in $K_m$ (Table 3).

### 3.4. Inhibitory effects of PPE-derived sitosterol-3-O-$\beta$-D-glucopyranoside against in vitro $\alpha$-amylase enzyme activity

Sitosterol-3-O-$\beta$-D-glucopyranoside isolated from PPE at the concentrations of 300, 1000 and 3000 $\mu$g/mL produced a significant inhibitory action against $\alpha$-amylase enzyme activity ($n = 3$, $P < 0.05$) (Table 5). The maximal inhibitory action (47.53 ± 5.59)$\%$ was found at the concentration of 1000 $\mu$g/mL.

### Table 5

The percentage of inhibition of PPE-derived sitosterol-3-O-$\beta$-D-glucopyranoside against $\alpha$-amylase enzyme activity, %.

<table>
<thead>
<tr>
<th>Sitosterol-3-O-$\beta$-D-glucopyranoside concentrations ($\mu$g/mL)</th>
<th>Inhibition</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0.00 ± 1.98</td>
</tr>
<tr>
<td>3</td>
<td>1.36 ± 0.63</td>
</tr>
<tr>
<td>10</td>
<td>5.28 ± 1.34</td>
</tr>
<tr>
<td>30</td>
<td>8.67 ± 2.02</td>
</tr>
<tr>
<td>100</td>
<td>25.78 ± 2.11$^a$</td>
</tr>
<tr>
<td>300</td>
<td>35.29 ± 1.46</td>
</tr>
<tr>
<td>1000</td>
<td>47.53 ± 5.59$^a$</td>
</tr>
<tr>
<td>3000</td>
<td>46.83 ± 1.51$^a$</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SD, $n = 3$. $^a$: $P < 0.05$ when compared with vehicle control (dimethyl sulfoxide). One-way ANOVA and Bonferroni post-hoc test were used.

PPE-derived sitosterol-3-O-$\beta$-D-glucopyranoside produced a concentration-dependent inhibition against $\alpha$-amylase enzyme with the IC$_{50}$ of (111.19 ± 9.02) $\mu$g/mL (mean ± SEM, $n = 3$) (Table 2). From the Lineweaver-Burk plot (Figure 1C), sitosterol-3-O-$\beta$-D-glucopyranoside isolated from PPE at the concentration of 100 $\mu$g/mL (estimated IC$_{50}$) provoked a decrease in both $V_{\text{max}}$ and $K_m$ (Table 3).

### Table 6

The percentage of inhibition of PPE against $\alpha$-glucosidase enzyme activity, %.

<table>
<thead>
<tr>
<th>PPE extract concentrations ($\mu$g/mL)</th>
<th>Inhibition</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0.00 ± 0.04</td>
</tr>
<tr>
<td>3</td>
<td>12.43 ± 1.84$^a$</td>
</tr>
<tr>
<td>10</td>
<td>10.35 ± 1.12$^a$</td>
</tr>
<tr>
<td>30</td>
<td>13.10 ± 1.67$^a$</td>
</tr>
<tr>
<td>100</td>
<td>14.51 ± 1.26$^a$</td>
</tr>
<tr>
<td>300</td>
<td>18.60 ± 1.29$^a$</td>
</tr>
<tr>
<td>1000</td>
<td>37.90 ± 2.62$^a$</td>
</tr>
<tr>
<td>3000</td>
<td>47.70 ± 2.13$^a$</td>
</tr>
<tr>
<td>5000</td>
<td>42.83 ± 2.79$^a$</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SD, $n = 4$. $^a$: $P < 0.05$ when compared with vehicle control (dimethyl sulfoxide). One-way ANOVA and Bonferroni post-hoc test were used.

of (43.86 ± 1.97)$\%$ was found with 200 $\mu$g/mL of acarbose. Median inhibitory concentration of (1.00 ± 0.11) mg/mL (mean ± SEM, $n = 4$) was obtained from the concentration-inhibitory response curve of PPE (Table 2).

$\alpha$-Glucosidase enzyme kinetics study was performed with various concentrations of $p$-NPG (0.037 5, 0.075, 0.15 and 0.30 IU/mL) in the presence or the absence of 1 mg/mL PPE (approximate IC$_{50}$). From the Lineweaver–Burk plot, PPE caused a decrease in $V_{\text{max}}$ without any change in $K_m$. On the contrary, acarbose induced changes in both $V_{\text{max}}$ and $K_m$, with a decrease in $V_{\text{max}}$ and an increase in $K_m$ (Table 7 and Figure 2).
Table 7
Changes of $V_{\text{max}}$ and $K_m$ of $\alpha$-glucosidase enzyme in the presence of the test agents.

<table>
<thead>
<tr>
<th>Agents</th>
<th>$\Delta V_{\text{max}}$ (unit of $p$-nitrophenol/min)</th>
<th>$\Delta K_m$ (unit/mL of $p$-NPG)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PPE</td>
<td>$-0.27$</td>
<td>$0$</td>
</tr>
<tr>
<td>Acarbose</td>
<td>$-0.09$</td>
<td>$+0.10$</td>
</tr>
</tbody>
</table>

Figure 2. Kinetics analysis of $\alpha$-glucosidase inhibition by PPE. Data are expressed as mean ± SEM, $n = 6$. Lineweaver–Burk plot of the reaction against $\alpha$-glucosidase in the presence of PPE (1 mg/mL) or acarbose (200 μg/mL).

3.6. Inhibitory effects of PPE-derived phytochemicals against in vitro $\alpha$-glucosidase enzyme activity

Stigmasterol and sitosterol-3-O-$\beta$-$D$-glucopyranoside, isolated from PPE, produced a concentration-independent inhibition against $\alpha$-glucosidase enzyme activity with a small inhibition of approximately 10% found at the concentrations of 0.1 and 1 μg/mL (Table 8).

Table 8
The percentage of inhibition of PPE-derived stigmasterol and sitosterol-3-O-$\beta$-$D$-glucopyranoside against $\alpha$-glucosidase enzyme activity, %.

<table>
<thead>
<tr>
<th>Concentrations (μg/mL)</th>
<th>Inhibition Stigmasterol</th>
<th>Inhibition Sitosterol-3-O-$\beta$-$D$-glucopyranoside</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.1</td>
<td>$12.42 \pm 1.52^*$</td>
<td>$13.84 \pm 3.24^*$</td>
</tr>
<tr>
<td>1</td>
<td>$10.22 \pm 1.81^*$</td>
<td>$14.04 \pm 1.85^*$</td>
</tr>
<tr>
<td>10</td>
<td>$5.47 \pm 1.84$</td>
<td>$12.79 \pm 0.52^*$</td>
</tr>
<tr>
<td>100</td>
<td>$6.05 \pm 0.93$</td>
<td>$8.68 \pm 0.95$</td>
</tr>
<tr>
<td>1000</td>
<td>$-4.37 \pm 4.01$</td>
<td>$7.11 \pm 3.55$</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SD, $n = 6$. *: $P < 0.05$ when compared with vehicle control (dimethyl sulfoxide). One-way ANOVA and Bonferroni post-hoc test were used.

3.7. Oral starch tolerance test

When PPE at the doses of 250, 500 and 1000 mg/kg body weight were given to the rats prior to oral starch feeding, a significant decrease in the blood glucose concentrations was found at 30 min after oral starch feeding (3 g/kg body weight) (Figure 3A). PPE at the doses of 250 and 1000 mg/kg body weight also significantly decreased the blood glucose levels at 60 min after oral starch feeding. However, PPE at any doses tested did not cause any significant change at 120 min after oral starch feeding. Stigmasterol and sitosterol-3-O-$\beta$-$D$-glucopyranoside, isolated from PPE, at the doses of 5 and 10 mg/kg also caused a significant decrease in blood glucose at $t = 30$ min.

3.8. Oral sucrose tolerance test

Treatment with either 250 mg/kg body weight PPE or 10 mg/kg body weight acarbose before oral sucrose feeding (4 g/kg body weight) significantly decreased the blood glucose levels at $t = 30$ min (Figure 4A). However, these treatments did not affect
the blood glucose levels at both $t = 60$ min and $t = 120$ min. Other treatments (500 and 1000 mg/kg body weight of PPE; 5 and 10 mg/kg body weight of stigmasterol; 5 and 10 mg/kg body weight of sitosterol-3-O-$\beta$-D-glucopyranoside) did not cause any significant decrease in the oral sucrose tolerance test (Figure 4).

4. Discussion

4.1. Inhibitory effects of PPE and its phytochemicals against in vitro and in vivo $\alpha$-amylase enzyme activity

PPE exhibited a concentration-dependent inhibitory action against in vitro $\alpha$-amylase enzyme activity with an IC$_{50}$ of $(11.79 \pm 8.10)$ mg/mL (mean $\pm$ SEM, $n = 6$). The maximal inhibitory action of $(89.79 \pm 3.42)\%$ was found at the concentration of 30 mg/mL. This is in accordance with our previous preliminary study in which a single IC$_{50}$ of 5 mg/mL was reported [7]. The experiment on $\alpha$-amylase enzyme kinetics showed that PPE (10 mg/mL) caused a decrease in $V_{\text{max}}$ and an increase in $K_{m}$. Thus, PPE inhibited $\alpha$-amylase enzyme in a mixed inhibition manner. This suggests that PPE can bind to either enzyme or enzyme–substrate complex to form enzyme–PPE complex or enzyme-substrate-PPE complex, respectively. Following these complex formations, $\alpha$-amylase enzyme is thus no longer available for catalyzing starch digestion. This mode of enzyme inhibition is similar to that of acarbose (Figure 1A). A mixed inhibitory action of acarbose against $\alpha$-amylase was also reported by Al Kazaz et al. [10] and Desseaux et al. [11]. It should be noted that 10 mg/mL PPE (approximate IC$_{50}$) and 100 $\mu$g/mL acarbose produced changes in both $V_{\text{max}}$ and $K_{m}$ at the comparable degrees (Table 3).

Stigmasterol derived from PPE possessed a concentration-dependent inhibitory action against $\alpha$-amylase enzyme with the IC$_{50}$ of $(59.41 \pm 8.22)$ $\mu$g/mL (mean $\pm$ SEM, $n = 3$). The maximal inhibition of $(42.68 \pm 3.69)\%$ ($n = 3$) was achieved at the concentration of 1000 $\mu$g/mL. Stigmasterol isolated from leaves of Dillenia indica ($D$. indica) at the concentration of 50 $\mu$g/mL inhibited $\alpha$-amylase enzyme activity by 48\% [12]. From the study of Kumar et al. [12], starch azure was used as a substrate and $\alpha$-amylase enzyme activity was indicated by the levels of its released product, Remazol Brilliant Blue R. The difference in methods used may partly explain the discrepancy of stigmasterol potency found between studies.

Sitosterol-3-$\beta$-$\beta$-D-glucopyranoside isolated from PPE possessed a concentration-dependent inhibitory action against in vitro $\alpha$-amylase enzyme activity with an IC$_{50}$ of $(111.19 \pm 9.02)$ $\mu$g/mL (mean $\pm$ SEM, $n = 3$). Nkobole et al. reported a slightly more potent $\alpha$-amylase inhibitory action of $\beta$-sitosterol isolated from Terminalia sericea bark, with the IC$_{50}$ of 216 $\mu$mol/L (89.57 $\mu$g/mL) [13]. It was also shown that $\beta$-sitosterol derived from leaves of $D$. indica at the concentration of 50 $\mu$g/mL inhibited $\alpha$-amylase enzyme activity by 45\% [12]. However, sitosterol-3-$\beta$-$\beta$-D-glucopyranoside at the concentration of 30 $\mu$g/mL exhibited a relatively low level of enzyme inhibition (8.67 $\pm$ 2.02)$\%$ in this study. These thus suggest that a sugar moiety presented in the chemical structure of isolated sitosterol-3-$\beta$-$\beta$-D-glucopyranoside possibly impedes its inhibitory action against $\alpha$-amylase enzyme.

The results from enzyme kinetics study indicated that stigmasterol exhibited its inhibitory action against $\alpha$-amylase in a mixed inhibition manner, whilst sitosterol-3-$\beta$-$\beta$-D-glucopyranoside exerted its enzyme inhibition in an uncompetitive fashion. Since PPE demonstrated a mixed inhibitory action against $\alpha$-amylase enzyme, stigmasterol is thus likely to be a primary phytochemical which plays a role in the $\alpha$-amylase inhibitory action of PPE. Nonetheless, further experiment should be done to explore whether these phytochemicals can produce either synergistic or antagonistic effect when they coexist. A mixed inhibitory mode of action of PPE proposes its advantage in the clinical use. A decrease in $V_{\text{max}}$ implies that the maximal rate of reaction would be lessened, regardless to the amount of ingested starch. Additionally, an increase in $K_{m}$ suggests that a substantially lower rate of reaction arises if a similar amount of starch is consumed.

The oral starch tolerance test is essential to prove whether the agents provoke a certain $\alpha$-amylase inhibitory action in vivo. PPE (250, 500 and 1000 mg/kg body weight) and its two isolated phytochemicals (stigmasterol and sitosterol-3-$\beta$-$\beta$-D-glucopyranoside, at 5 and 10 mg/kg body weight) caused a significant decrease in the blood glucose levels at $t = 30$ min. Thus, the inhibitory action of PPE against starch digestion in vivo potentially arises from the actions of these two phytochemicals. At $t = 60$ min, PPE at the doses of 250 and 1000 mg/kg body weight significantly decreased the blood glucose levels. However, neither stigmasterol nor sitosterol-3-$\beta$-$\beta$-D-glucopyranoside lowered the blood glucose levels at $t = 60$ min. It is possible that the given doses of these two phytochemicals were not sufficient to inhibit in vivo $\alpha$-amylase enzyme activity at $t = 60$ min, when an adaptive increase of $\alpha$-amylase enzyme secretion may develop in vivo. PPE and its phytochemicals did not produce a substantial change in the blood glucose level at $t = 120$ min. This suggests that PPE exerted its action in a reversible manner, which may reduce a risk of adverse drug reactions caused by an indigestible carbohydrate in the intestine. Acarbose also showed the blood glucose-lowering action only at $t = 30$ min and $t = 60$ min. Thus, both PPE and acarbose exhibited their blood glucose-lowering action at a similar period of time. To our knowledge, this is the first report of the in vivo $\alpha$-amylase inhibitory action of PPE and its isolated phytochemicals.

4.2. Inhibitory effects of PPE and its phytochemicals against in vitro and in vivo $\alpha$-glucosidase enzyme activity

PPE significantly inhibited in vitro $\alpha$-glucosidase enzyme activity with the maximal inhibition of $(47.70 \pm 2.13)\%$ and the IC$_{50}$ of $(1.00 \pm 0.11)$ mg/mL. The methanolic extract of $P$. palatiferum leaves (1 mg/mL) was reported to have a slight $\alpha$-glucosidase inhibitory action of 7\% [14]. This is different from our results in which 1 mg/mL of PPE exhibited a considerable $\alpha$-glucosidase inhibition of approximately 40\%. The difference in the solvent used in the preparation of the extract may partly be the reason for this discrepancy. Enzyme kinetics study revealed that PPE exhibited a non-competitive inhibition against $\alpha$-glucosidase enzyme, whilst acarbose inhibited the enzyme in a mixed inhibition manner.

Stigmasterol and sitosterol-3-$\beta$-$\beta$-D-glucopyranoside extracted from PPE possessed a weak and non-concentration-dependent $\alpha$-glucosidase inhibition. Stigmasterol and $\beta$-sitosterol (50 $\mu$g/mL) isolated from $D$. indica leaves was shown to inhibit $\alpha$-glucosidase enzyme by 34.2\% and 52.5\%, respectively.
[12], The differences between the studies cannot be justified yet. However, a purification process of the isolated phytochemicals may be involved.

From the oral sucrose tolerance test, PPE only at the dose of 250 mg/kg caused a significant depletion of the blood glucose at t = 30 min. However, neither stigmastanol nor sitosterol-3-O-β-D-glucopyranoside at the tested doses caused a significant decrease in the blood glucose at any time examined. It is possible that other unknown phytochemicals may be responsible for the in vivo α-glucosidase inhibition of PPE. The other phytochemicals found in the PPE include flavonoids and its derivatives such as kaempferol-3-methyl ether-7-O-β-glucoside and apigenin-7-O-β-glucoside [15]. Both kaempferol and apigenin were shown to have in vitro α-glucosidase inhibitory action [16]. Nonetheless, it cannot be excluded that the doses of phytochemicals used in this study are possibly insufficient to inhibit the enzyme activity in vivo.

PPE and its phytochemicals were shown to decrease the fasting plasma glucose levels in the diabetic rats [5,6]. However, their mechanism of anti-diabetic action has not been established. Recently, anti-lipolytic and antioxidative activities of PPE were described to be linked with its anti-diabetic efficacy [7]. The in vitro and in vivo α-amylase and α-glucosidase inhibitions of PPE addressed herein further steadily explain its mechanism of anti-diabetic action. The current in vitro and in vivo experiments suggest that stigmastanol and sitosterol-3-O-β-glucopyranoside are likely to be the active phytochemicals acting as α-amylase enzyme inhibitors. However, the inhibitory action of these isolated phytochemicals against α-glucosidase enzyme is scanty.

Postprandial hyperglycemia is implicated in chronic diabetic complications and pancreatic beta-cell destruction [2,17,18]. A restriction of intestinal carbohydrate digestion thus likely conduces to a better control of diabetes. Both α-amylase and α-glucosidase enzymes play a crucial role in an intestinal digestion of complex carbohydrate, which is commonly found in a diet. The dual inhibitory actions of PPE against these enzymes suggest its advantage over a sole inhibition on each enzyme alone. Although the current in vitro and in vivo experiments suggest the potential therapeutic benefit of PPE, further clinical study is still required to confirm its efficacy and safety.

In conclusion, PPE and its isolated phytochemicals, stigmastanol and sitosterol-3-O-β-glucopyranoside significantly inhibited both in vitro and in vivo α-amylase enzyme activity. PPE also produced an appreciable inhibitory action against α-glucosidase enzyme both in vitro and in vivo. However, the two extracted phytochemicals are unlikely to act as an active compound against α-glucosidase enzyme. These results thus provide a scientific support for a traditional use of P. palatiferum leaves in the treatment of diabetes. Nonetheless, further clinical study is necessary to verify its role in the clinical management of diabetes.

Conflict of interest statement

We declare that we have no conflict of interest.

Acknowledgments

This study was funded by Mahasarakham University research grant (Grant No. 5805028/2558, fiscal year 2015).

References


